Clinical outcome of adding long-acting β-agonists to inhaled corticosteroids

被引:12
作者
Barnes, PJ [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England
关键词
formoterol; corticosteroid; budesonide; exacerbation;
D O I
10.1053/rmed.2001.1140
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Current asthma management guidelines state that where a patient is receiving a low to moderate dose of inhaled corticosteroids and is still experiencing symptoms the dose of corticosteroid should be increased and, if necessary, a long-acting bronchodilator should be added. Many studies have now shown that the addition of a beta (2)-agonist with long-acting properties is more effective at controlling asthma symptoms than increasing the dose of corticosteroid alone. The Formoterol and Corticosteroid Establishing Therapy (FACET) study was a 12-month study comparing exacerbation rates in patients treated with budesonide (100 mug or 400 mug) twice daily alone vs. treatment with budesonicle (100 mug or 400 mug) twice daily plus formoterol 9 mug twice daily (delivered dose) (1). The addition of formoterol reduced the rates of mild and severe exacerbations compared with budesonide alone, with the lowest rates seen in patients receiving high-dose budesonicle and formoterol. There was no difference in the profile of exacerbations in any groups, indicating formoterol does not mask any signs of inflammation, The addition of formoterol to budesonicle was also shown to result in improved lung function (as measured by peak expiratory flow rate and forced expiratory volume in I second), night-time awakenings and the use of as-needed medication when compared with an increase in the dose of budesonicle. In all cases, increasing the dose of budesonicle and addition of formoterol resulted in the most improvement and a significant increase in quality of life, measured by Asthma Quality of Life Questionnaire (AQLQ), was noted. In conclusion, the addition of formoterol to established treatment with inhaled corticosteroids provides superior asthma control compared with an increase in the dose of corticosteroid alone. (C) 2001 Harcourt Publishers Ltd.
引用
收藏
页码:S12 / S16
页数:5
相关论文
共 18 条
  • [1] Adding formoterol to budesonide in moderate asthma -: health economic results from the FACET study
    Andersson, F
    Ståhl, E
    Barnes, PJ
    Löfdahl, CG
    O'Byrne, PM
    Pauwels, RA
    Postma, DS
    Tattersfield, AE
    Ullman, A
    [J]. RESPIRATORY MEDICINE, 2001, 95 (06) : 505 - 512
  • [2] Barnes PJ, 2000, THORAX, V55, pA4
  • [3] Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma
    Busse, WW
    Chervinsky, P
    Condemi, J
    Lumry, WR
    Petty, TL
    Rennard, S
    Townley, RG
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 101 (04) : 457 - 463
  • [4] Regular inhaled salbutamol and asthma control: the TRUST randomised trial
    Dennis, SM
    Sharp, SJ
    Vickers, MR
    Frost, CD
    Crompton, GK
    Barnes, PJ
    Lee, TH
    [J]. LANCET, 2000, 355 (9216) : 1675 - 1679
  • [5] Comparison of regularly scheduled with as-needed use of albuterol in mild asthma
    Drazen, JM
    Israel, E
    Boushey, HA
    Chinchilli, VM
    Fahy, JV
    Fish, JE
    Lazarus, SC
    Lemanske, RF
    Martin, RJ
    Peters, SP
    Sorkness, C
    Szefler, SJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (12) : 841 - 847
  • [6] Ligand-independent activation of the glucocorticoid receptor by β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells
    Eickelberg, O
    Roth, M
    Lörx, R
    Bruce, V
    Rüdiger, J
    Johnson, M
    Block, LH
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (02) : 1005 - 1010
  • [7] ADDED SALMETEROL VERSUS HIGHER-DOSE CORTICOSTEROID IN ASTHMA PATIENTS WITH SYMPTOMS ON EXISTING INHALED CORTICOSTEROID
    GREENING, AP
    IND, PW
    NORTHFIELD, M
    SHAW, G
    [J]. LANCET, 1994, 344 (8917) : 219 - 224
  • [8] Asthma quality of life during 1 year of treatment with budesonide with or without formoterol
    Juniper, EF
    Svensson, K
    O'Byrne, PM
    Barnes, PJ
    Bauer, CA
    Löfdahl, CGA
    Postma, DS
    Pauwels, RA
    Tattersfield, AE
    Ullman, A
    [J]. EUROPEAN RESPIRATORY JOURNAL, 1999, 14 (05) : 1038 - 1043
  • [9] Pharmacological similarities and differences between β2-agonists
    Lötvall, J
    [J]. RESPIRATORY MEDICINE, 2001, 95 : S7 - S11
  • [10] Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma
    Nightingale, JA
    Rogers, DF
    Barnes, PJ
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 159 (06) : 1786 - 1790